COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #220 of 237
12/23 Early treatment study
Su et al., BioScience Trends, doi:10.5582/bst.2020.03340 (Peer Reviewed)
Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China
Source   PDF   Share   Tweet
85% lower disease progression with early use of HCQ. Retrospective 616 patients in China showing adjusted progression HR 0.15, p = 0.006.

Su et al., 12/23/2020, retrospective, China, Asia, peer-reviewed, 9 authors, dosage 400mg days 1-10, 400mg daily for 10-14 days.
risk of disease progression, 84.9% lower, RR 0.15, p = 0.006, treatment 261, control 355, adjusted per study, binary logistic regression.
improvement time, 24.0% lower, relative time 0.76, p = 0.02, treatment 261, control 355, adjusted per study, Cox proportional hazards regression.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit